Ophthalmic Disease Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma {Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists}), By Dosage Form (Solid, Liquid, & Semisolid), By Disease Indication (Glaucoma {Open Angle Glaucoma, Angle Closure Glaucoma}, Dry Eye Disease, Retinal Diseases {Diabetic Macular Edema, Macular Degeneration}, Allergy & Infections), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), & Regional Forecast, 2024-2032

Last Updated: December 08, 2025 | Format: PDF | Report ID: FBI100441

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 6.5% from 2024-2032
Unit	Value (USD billion)
Segmentation	By Drug Class Anti-inflammatory Anti-infectives Anti-VEGF Anti-glaucoma Beta Blockers Prostaglandins Analogs Alpha Adrenergic Agonists Carbonic Anhydrase Inhibitors Combination Drugs Others Others
	By Dosage Form Solid Liquid Semisolid
	By Disease Indication Glaucoma Open Angle Glaucoma Angle Closure Glaucoma Others Dry Eye Disease Retinal Diseases Diabetic Macular Edema (DME) Macular Degeneration (AMD) Diabetic Retinopathy (DR) Retinal Vein Occlusion (RVO) Others Allergy & Infections Others
	By Distribution Channel Hospital Pharmacies Retail & Online Pharmacies
	By Region North America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country) U.S. Canada Europe (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region) Germany U.K. France Italy Spain Scandinavia Rest of Europe Asia Pacific (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region) GCC South Africa Rest of Middle East & Africa